search
Back to results

Semaglutide Therapy for Alcohol Reduction - Tulsa (STAR-T)

Primary Purpose

Alcohol Use Disorder

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Semaglutide
Placebo
Sponsored by
Oklahoma State University Center for Health Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol Use Disorder focused on measuring Alcohol, Ozempic, Wegovy, Semaglutide, Addiction, Substance Use, Alcohol drinking, Alcohol-Related Disorders

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Ability to provide informed consent before any trial-related activities Male or female individuals who are at least 18 years old Alcohol Use Disorder (minimum 2 symptoms on a validated diagnostic tool, e.g., DSM-5 Checklist for Alcohol Use Disorder, the Mini-International Neuropsychiatric Interview (MINI) or the Structured Clinical Interview for DSM Disorders (SCID)) Self-reported drinking, according to alcohol TimeLine Follow-Back (TLFB), of > 7 drinks per week for females or > 14 drinks per week for males during the 28-day period prior to screening + at least four days with > 3 drinks for females or > 4 drinks for males during the 28-day period prior to screening. Most recent Clinical Institute Withdrawal Assessment for Alcohol - revised (CIWA-Ar) score is ≤ 10 Able to speak, read, write, and understand English Normal or corrected-to-normal (e.g., wearing glasses or contacts) vision and normal or corrected-to-normal (e.g., with the use of a hearing aid) hearing Female participants must be postmenopausal for at least one year, surgically sterile, or practicing a highly effective method of birth control before entry and throughout the study and must have a negative urine pregnancy test at each visit. Examples of birth control methods include (but are not limited to) oral contraceptives or contraceptive implants, barrier methods such as diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms, intrauterine devices, a partner with a vasectomy, or abstinence from intercourse. Exclusion Criteria: BMI < 25 kg/m2 or BMI ≥ 50 kg/m2 Evidence of malnutrition as determined by the Nutrition Risk Screening 2002 (NRS-2002) Most recent blood tests: creatinine ≥ 2 mg/dL, eGFR ≤ 60 mL/min/1.73 m2, triglycerides > 500 mg/dl, ALP > 4x the upper normal limit, abnormal blood lipase levels Present diagnosis of diabetes or blood hemoglobin A1c (HbA1c) ≥ 6.5 % Current use of the following medications with glucose lowering properties: GLP-1 analogues, sulfonylurea, insulin, metformin, thiazolidinediones (TZD), dipeptidyl peptidase-4 (DPP-IV) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors Current or prior use of semaglutide (Ozempic or Wegovy) or tirzepatide (Mounjaro). Use of weight-lowering/anti-obesity medications within the past 90 days prior to enrollment in the study. Current use of FDA-approved pharmacotherapy for AUD (acamprosate, disulfiram, naltrexone), or other medications that are used for AUD treatment including topiramate and bupropion. Due to the half-life of injectable naltrexone, we will exclude participants who have taken vivitrol in the past 30 days. Current use of medications with known interactions with semaglutide Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known history of alcoholic ketoacidosis, pancreatitis (either acute or chronic), pancreatic carcinoma, gallbladder disease, jaundice, Mallory-Weiss syndrome (esophageal tears secondary to vomiting), esophageal varices, cirrhosis Known history of gastric bypass surgery Known or suspected allergy to semaglutide, any of the product components, or any other GLP-1 analogue Known history of suicidal attempts (within the past 24 months) or active suicidal ideation Known history of vestibular disorders or clinically significant motion sickness Known history of noise-induced hearing loss or tinnitus Only for subjects undergoing brain scan: contraindication(s) for brain fMRI Unstable cardiovascular conditions (e.g., arrhythmias, clinically significant ECG abnormalities) Physical and/or mental health conditions that are clinically unstable, as determined by the study clinicians, including (but not limited to) major depressive disorder or generalized anxiety disorder unstable within the past three months or other psychiatric conditions (e.g., schizophrenia, bipolar disorder) unstable within the past twelve months. Current stimulant or opioid use disorder. Any other reason or clinical condition that the Investigators judge would interfere with study participation and/or be unsafe for a possible subject

Sites / Locations

  • OSU Biomedical Imaging CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Semaglutide

Placebo

Arm Description

Participants will receive subcutaneous injections of semaglutide in escalating doses (.25mg to 1.0mg) over the course of 12 weeks.

Participants will receive subcutaneous injections of a placebo saline solution over the course of 12 weeks.

Outcomes

Primary Outcome Measures

Change in alcohol drinking
Difference in number of standard alcoholic drinks consumed/week (Drinks Per Week, DPW)

Secondary Outcome Measures

Change in heavy drinking days
Difference in number of heavy drinking days as reported in Alcohol TLFB
Change in drinks per drinking days
Difference in number of drinks per drinking days as reported in Alcohol TLFB
Safety and tolerability of semaglutide in individuals with alcohol use disorder (AUD)
Number and grade of adverse events in individuals with AUD who receive semaglutide or placebo
Reduction and/or changes in food choices in a virtual reality buffet-like laboratory
Difference in the macronutrient content selected in the virtual reality buffet
Change in blood phosphatidylethanol (PEth) levels as a biomarker of alcohol use
Difference in blood PEth levels
Changes in brain activity in response to alcohol cues during fMRI cue reactivity task
Group differences in fMRI blood oxygenation level dependent (BOLD) signal within reward neurocircuitry in response to alcohol and nonalcoholic beverage stimuli
Changes in brain activity during an fMRI interoceptive attention task
Group differences in fMRI blood oxygenation level dependent (BOLD) signal within interoceptive brain regions during an interoceptive attention task.
Changes in brain activity during an alcohol-related Go/No-Go fNIRS task
Difference in activity of inhibitory brain regions during an alcohol-related Go/No-Go fNIRS task.

Full Information

First Posted
May 4, 2023
Last Updated
June 14, 2023
Sponsor
Oklahoma State University Center for Health Sciences
Collaborators
National Institute of Drug Abuse
search

1. Study Identification

Unique Protocol Identification Number
NCT05891587
Brief Title
Semaglutide Therapy for Alcohol Reduction - Tulsa
Acronym
STAR-T
Official Title
Semaglutide Therapy for Alcohol Reduction - Tulsa
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 2023 (Anticipated)
Primary Completion Date
June 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Oklahoma State University Center for Health Sciences
Collaborators
National Institute of Drug Abuse

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.
Detailed Description
This is a randomized, double-blind, placebo-controlled clinical trial assessing the efficacy and tolerability of semaglutide in individuals who meet criteria for alcohol use disorder. Participants will complete a remote phone screening and an on-site screening visit to determine study eligibility. Eligible participants will be randomized to receive weekly subcutaneous injections of either semaglutide or a placebo (1:1 ratio). Doses will be titrated according to the FDA-approved dosing schedule starting at a dose of 0.25 mg/week for four weeks, then 0.5 mg/week for four weeks, and finally the dose will be increased to 1.0 mg/week for four weeks, for a total of 12 weeks of treatment. Participants will be asked to complete experimental procedures at the baseline and endpoint visits (Week 1 and Week 12), which include functional magnetic resonance imaging (fMRI) experiments, functional near-infrared spectroscopy (fNIRS) experiments, and virtual reality experiments. Participants will also complete questionnaires, biospecimen collections, and computer-based behavioral therapy modules at various study timepoints. Participants will periodically meet with a study physician and will be monitored for any adverse events. A remote follow-up assessment will take place 9 weeks after the participant's last dosing visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Use Disorder
Keywords
Alcohol, Ozempic, Wegovy, Semaglutide, Addiction, Substance Use, Alcohol drinking, Alcohol-Related Disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized, between-subject, double-blind, and placebo-controlled.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Semaglutide
Arm Type
Experimental
Arm Description
Participants will receive subcutaneous injections of semaglutide in escalating doses (.25mg to 1.0mg) over the course of 12 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive subcutaneous injections of a placebo saline solution over the course of 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Semaglutide
Intervention Description
Semaglutide pen injector
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Saline solution
Primary Outcome Measure Information:
Title
Change in alcohol drinking
Description
Difference in number of standard alcoholic drinks consumed/week (Drinks Per Week, DPW)
Time Frame
Baseline (Week 1) to post-medication (Week 13
Secondary Outcome Measure Information:
Title
Change in heavy drinking days
Description
Difference in number of heavy drinking days as reported in Alcohol TLFB
Time Frame
Baseline (Week 1) to post-medication (Week 13)
Title
Change in drinks per drinking days
Description
Difference in number of drinks per drinking days as reported in Alcohol TLFB
Time Frame
Baseline (Week 1) to post-medication (Week 13)
Title
Safety and tolerability of semaglutide in individuals with alcohol use disorder (AUD)
Description
Number and grade of adverse events in individuals with AUD who receive semaglutide or placebo
Time Frame
Baseline (Week 1) to post-medication (Week 13)
Title
Reduction and/or changes in food choices in a virtual reality buffet-like laboratory
Description
Difference in the macronutrient content selected in the virtual reality buffet
Time Frame
Baseline (Week 1) to post-medication (Week 13)
Title
Change in blood phosphatidylethanol (PEth) levels as a biomarker of alcohol use
Description
Difference in blood PEth levels
Time Frame
Baseline (Week 1) to post-medication (Week 13)
Title
Changes in brain activity in response to alcohol cues during fMRI cue reactivity task
Description
Group differences in fMRI blood oxygenation level dependent (BOLD) signal within reward neurocircuitry in response to alcohol and nonalcoholic beverage stimuli
Time Frame
Baseline (Week 1) to post-medication (Week 13)
Title
Changes in brain activity during an fMRI interoceptive attention task
Description
Group differences in fMRI blood oxygenation level dependent (BOLD) signal within interoceptive brain regions during an interoceptive attention task.
Time Frame
Baseline (Week 1) to post-medication (Week 13)
Title
Changes in brain activity during an alcohol-related Go/No-Go fNIRS task
Description
Difference in activity of inhibitory brain regions during an alcohol-related Go/No-Go fNIRS task.
Time Frame
Baseline (Week 1) to post-medication (Week 13)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ability to provide informed consent before any trial-related activities Male or female individuals who are at least 18 years old Alcohol Use Disorder (minimum 2 symptoms on a validated diagnostic tool, e.g., DSM-5 Checklist for Alcohol Use Disorder, the Mini-International Neuropsychiatric Interview (MINI) or the Structured Clinical Interview for DSM Disorders (SCID)) Self-reported drinking, according to alcohol TimeLine Follow-Back (TLFB), of > 7 drinks per week for females or > 14 drinks per week for males during the 28-day period prior to screening + at least four days with > 3 drinks for females or > 4 drinks for males during the 28-day period prior to screening. Most recent Clinical Institute Withdrawal Assessment for Alcohol - revised (CIWA-Ar) score is ≤ 10 Able to speak, read, write, and understand English Normal or corrected-to-normal (e.g., wearing glasses or contacts) vision and normal or corrected-to-normal (e.g., with the use of a hearing aid) hearing Female participants must be postmenopausal for at least one year, surgically sterile, or practicing a highly effective method of birth control before entry and throughout the study and must have a negative urine pregnancy test at each visit. Examples of birth control methods include (but are not limited to) oral contraceptives or contraceptive implants, barrier methods such as diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms, intrauterine devices, a partner with a vasectomy, or abstinence from intercourse. Exclusion Criteria: BMI < 25 kg/m2 or BMI ≥ 50 kg/m2 Evidence of malnutrition as determined by the Nutrition Risk Screening 2002 (NRS-2002) Most recent blood tests: creatinine ≥ 2 mg/dL, eGFR ≤ 60 mL/min/1.73 m2, triglycerides > 500 mg/dl, ALP > 4x the upper normal limit, abnormal blood lipase levels Present diagnosis of diabetes or blood hemoglobin A1c (HbA1c) ≥ 6.5 % Current use of the following medications with glucose lowering properties: GLP-1 analogues, sulfonylurea, insulin, metformin, thiazolidinediones (TZD), dipeptidyl peptidase-4 (DPP-IV) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors Current or prior use of semaglutide (Ozempic or Wegovy) or tirzepatide (Mounjaro). Use of weight-lowering/anti-obesity medications within the past 90 days prior to enrollment in the study. Current use of FDA-approved pharmacotherapy for AUD (acamprosate, disulfiram, naltrexone), or other medications that are used for AUD treatment including topiramate and bupropion. Due to the half-life of injectable naltrexone, we will exclude participants who have taken vivitrol in the past 30 days. Current use of medications with known interactions with semaglutide Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known history of alcoholic ketoacidosis, pancreatitis (either acute or chronic), pancreatic carcinoma, gallbladder disease, jaundice, Mallory-Weiss syndrome (esophageal tears secondary to vomiting), esophageal varices, cirrhosis Known history of gastric bypass surgery Known or suspected allergy to semaglutide, any of the product components, or any other GLP-1 analogue Known history of suicidal attempts (within the past 24 months) or active suicidal ideation Known history of vestibular disorders or clinically significant motion sickness Known history of noise-induced hearing loss or tinnitus Only for subjects undergoing brain scan: contraindication(s) for brain fMRI Unstable cardiovascular conditions (e.g., arrhythmias, clinically significant ECG abnormalities) Physical and/or mental health conditions that are clinically unstable, as determined by the study clinicians, including (but not limited to) major depressive disorder or generalized anxiety disorder unstable within the past three months or other psychiatric conditions (e.g., schizophrenia, bipolar disorder) unstable within the past twelve months. Current stimulant or opioid use disorder. Any other reason or clinical condition that the Investigators judge would interfere with study participation and/or be unsafe for a possible subject
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Katie Thompson, LMSW
Phone
‪(405) 860-0069‬
Email
kthom58@okstate.edu
First Name & Middle Initial & Last Name or Official Title & Degree
William K Simmons, Ph.D.
Email
kyle.simmons@okstate.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William K Simmons, Ph.D.
Organizational Affiliation
Oklahoma State University Center for Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
OSU Biomedical Imaging Center
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74136
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William K Simmons, Ph.D.
Email
kyle.simmons@okstate.edu
First Name & Middle Initial & Last Name & Degree
William K Simmons, Ph.D.
First Name & Middle Initial & Last Name & Degree
Kelly Dunn, M.D.

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
IPD will be shared with other investigators upon reasonable request.
IPD Sharing Time Frame
Data will become available following publication of study manuscripts and will be available indefinitely.
IPD Sharing Access Criteria
Reasonable request from qualified investigator.

Learn more about this trial

Semaglutide Therapy for Alcohol Reduction - Tulsa

We'll reach out to this number within 24 hrs